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While genetic testing for familial cancer susceptibility fac-
tors has excelled in recent years, the prevention options
for those carrying high risk alleles have not. Altered bioe-
nergetics has now been acknowledged as an emerging
hallmark of cancer, and is believed to be a critical charac-
teristic acquired during tumorigenesis. Several very safe
drugs are available that can modify bioenergetics. Dichlor-
oacetate (DCA) inactivates pyruvate dehydrogenase kinase,
resulting in activation of pyruvate dehydrogenase, reduced
lactic acid production and increased mitochondrial activ-
ity. Metformin, a type 2 diabetes treatment which activates
AMPK, thereby inhibiting mTOR, has unambiguously
been demonstrated to reduce the risk of many cancer
types in diabetics where insulin treatments do not. We
have tested these drugs as chemopreventive agents against
the mammary tumours that occur in the spontaneous
BALB/c-Trp53+/- mouse tumour model.
In vitro studies on breast cancer cell lines indicate that
DCA (1-5 mM), metformin (30-300 uM) or the combi-
nation of the two can significantly inhibit breast cancer
cell growth over 4 days of treatment. These results sup-
port the possibility that DCA and metformin could pre-
vent or delay breast cancer formation in BALB/c-Trp53
+/- mice. To examine this, four groups of female BALB/
c-Trp53+/- mice were given distilled water (n=75), DCA
(1.5 g/L in drinking water, ~180 mg/kg/day, n=53), met-
formin (0.25 g/L in drinking water, ~30 mg/kg/day,
n=61) or DCA + metformin (n=51) from 8 weeks of
age, and monitored for tumour development over 78
weeks. The overall tumour-free survival curves were not
significantly different (Kaplan-Meier analysis) between
the treatment groups, suggesting that metformin does
not reduce cancer risk in non-diabetics. However, the
occurrence of mammary tumours in the four groups
was altered. DCA reduced the number and increased
the latency of mammary tumours (20.8% of DCA treated
mice with mean latency of 63.8 weeks compared to
28.0% of untreated mice with mean latency of 55.0
weeks), whereas metformin had no effect (26.2% of
mice, average latency 54.7 weeks). Examining the mam-
mary tumour-free survival curves, DCA appeared to
eliminate the early onset mammary tumours (latency
<52 weeks, p=0.02), while not affecting the occurrence
o fl o n g e rl a t e n c yt u m o u r s .W ea r ec u r r e n t l ye x a m i n i n g
these tumours to identify characteristics that may
explain this difference in sensitivity to DCA prevention.
Contrasting with the in vitro cancer cell line result, the
two drug combination had worse outcomes for tumour
development, with 35.3% of mice developing mammary
tumours with a decreased latency of 48.8 weeks (p<0.02
compared to DCA alone). Preliminary western blotting
results in MDA-MB-468 breast cancer cells found that
DCA could block the activation of AMPK by metformin,
indicating the potential for drug interactions. However,
the outcomes of these drug interactions clearly differs in
the fully transformed cancer cell (growth inhibition)
compared to the preneoplastic cell (survival / growth
advantage) and requires further investigation.
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